Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

SalMar to present Q1 2026 results on May 20 with live webcast and Q&A session

Company Fundamentals
13 May 2026
Na
View Source
Neutral
pluang ai news

SalMar ASA will present its first quarter 2026 financial results on May 20, 2026, at 08:00 CEST at Hotel Continental in Oslo. The presentation will be led by CEO Frode Arntsen and CFO Ulrik Steinvik and will be available live via Norwegian webcast with an opportunity for questions. An English webcast recording will be available later the same day. The results will be published earlier at 06:30 CET on the company's and Oslo Stock Exchange's websites. This event provides investors with timely insights into SalMar's recent performance and outlook.

More News

U-BX Technology shares drop 15.6% after announcing a 1-for-25 reverse stock split.

U-BX Technology shares drop 15.6% after announcing a 1-for-25 reverse stock split.

U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...

Company Fundamentals
Bearish
1 hour ago
Accel Entertainment shows steady earnings but limited growth, holding at 5.7x EV/EBITDA with cautious outlook.

Accel Entertainment shows steady earnings but limited growth, holding at 5.7x EV/EBITDA with cautious outlook.

Accel Entertainment has maintained steady earnings growth and strong video gaming terminal distribution outside Illinois, but its stock remains rangebound since mid-2023. The company faces limited near-term upside due to higher operating costs and un...

Analyst Insights
Neutral
4 hours ago
Hansa Biopharma licenses IDEFIRIX to SERB for €115M, boosting EU and MENA market presence and US launch funding.

Hansa Biopharma licenses IDEFIRIX to SERB for €115M, boosting EU and MENA market presence and US launch funding.

Hansa Biopharma has entered an exclusive licensing agreement with SERB S.A. for the development and commercialization of IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and MENA regions. This deal includes an upf...

Company Fundamentals
Bullish
4 hours ago
Vanguard Utilities ETF rated Buy with 12-14% return amid $1.3T CapEx from AI data centers.

Vanguard Utilities ETF rated Buy with 12-14% return amid $1.3T CapEx from AI data centers.

The Vanguard Utilities Index Fund ETF (VPU) is rated a Buy, with a projected return of 12-14%. This positive outlook is driven by a $1.3 trillion capital expenditure cycle fueled by rising electricity demand from AI data centers. The CapEx cycle supp...

Analyst Insights
Bullish
4 hours ago
Avacta reports £38.6M loss in 2025, advances cancer drug trials, and raises £10M to fund R&D into 2027

Avacta reports £38.6M loss in 2025, advances cancer drug trials, and raises £10M to fund R&D into 2027

Avacta Therapeutics posted a £38.6 million loss for 2025 amid strategic focus on its proprietary pre|CISION® cancer drug platform. The company progressed two clinical-stage programs, AVA6000 and AVA6103, showing promising safety and efficacy data, es...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App